It’s been an exciting time for TCB. As we approach 100 staff at our HQ our growing teams are supporting global efforts to fight cancer. This month we’ve opened two new offices. In Leiden, The Netherlands, our new satellite adds to our first international office in Japan and demonstrates our expanding international footprint. The office there will primarily be used as an EU base to support our European clinical efforts, and can seed future strategic operational growth as required. In Central London, our new office provides us with a base which is close to regulators, collaborators and the UK's financial centre. All of our product development, manufacturing and quality functions will continue to be built upon the first-class facilities we enjoy at Maxim Park near Glasgow, with these openings reflecting the global nature of the biotech business and the international fight against cancer.